About Sunil Singhal, M.D.
Form D filings for MorphImmune from 2022 to 2023 list Sunil Singhal, M.D. as director.
Sunil Singhal, M.D. first appears on SEC filings in 2022.
Experience
This experience comes from SEC filings. The years are when the filings name Sunil Singhal, M.D. in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Sunil Singhal, M.D. works with at each company, as listed on that company's latest Form D.
MorphImmune Inc. · Form D, May 17, 2023
PD
Philip Low, Ph.D.
Director
IB
Isaac Barchas
Director
CD
Clay Siegall, Ph.D.
President and Chief Executive Officer, director
RM
Ronald Martell
Director
FD